Acrux (ASX:ACR) is set to bring its transdermal Estradiol spray Lenzetto® to the Australian market after expanding its licensing agreement with long-term partner Gedeon Richter Plc. The move could deliver Acrux up to AUD 5.4 million in milestone payments over a set period. The amended agreement comes at a critical time for Australian women, with
Read More
What’s in a brand name, when household income has been squeezed to its very last drop? Rising costs have compelled people to opt for generic meds instead of branded ones to save a few bucks wherever possible. And now, meds for chronic anal fissure pain are set to get a generic version, thanks to pharma
Read More
Aussie pharmaceuticals company Acrux (ASX: ACR) is quickly making inroads through the lucrative American healthcare system with regulatory approval granted for their generic equivalent of a common testosterone topical solution which generates more than $25 million annually. Approval was granted from the Food and Drug administration for Acrux’s gel following their submission in August 2018
Read More